Senator Leahy Visits BioTek to Celebrate Manufacturing Milestone
May 27, 2010
Vermont Senator Patrick Leahy visited BioTek Instruments on April 26, 2010 to mark the manufacture and shipment of the 1000th Galileo Echo automated blood testing instrument. The Galileo Echo is used in blood banks and hospital laboratories to accurately type and sub-type blood for transfusion, and is designed and manufactured by BioTek exclusively for Immucor, Inc. (Norcross, GA), a leading manufacturer of blood analysis reagents and systems.
In addition to the company-wide celebration of this successful Immucor partnership, BioTek also noted that it continues to grow and flourish in Vermont. "As a private company, we are able to focus on long-term goals, not short-term financial gains," noted Briar Alpert, President and CEO of BioTek Instruments. "This includes long-term partnerships with companies like Immucor, and long-term investments in the skills and well-being of our employees."
Vermont Senator Patrick Leahy joined key BioTek and Immucor employees in signing the 1000th Echo instrument, saying, "BioTek's production of the 1,000th Galileo Echo is as much a cause for celebration here in Vermont as it is across the globe, where these machines are helping to more cost effectively and accurately identify and cross match blood types in hospitals, medical laboratories and blood banks."
Commenting on BioTek’s success within Vermont, Senator Leahy continued, "BioTek's success, even in this difficult economy, is proof that businesses of tomorrow can succeed in Vermont today. This milestone is also a testament to the Alpert family's commitment to innovative business practices, to their customers, to Vermont and to their workforce."
Click here to watch a video of the 1000th Galileo Echo Celebration.
BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. BioTek instrumentation is used to aid in the advancement of life science research, facilitate the drug discovery process and to enable cost-effective quantification of disease relevant molecules in the clinic.
For further information, contact:
Chere Griffin, Account Executive
Shaw & Todd Advertising and Marketing Communications